PARP inhibitors – Medxy AI

Comprehensive Overview of the AMPLITUDE Trial Results on Niraparib and AAP in HRR-Deficient Prostate Cancer

By MedXY 11/12/2025

The AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improves progression-free survival in HRR-deficient metastatic prostate cancer, with maintained quality of life and manageable safety in advanced clinical settings.

news Oncology Urology

Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort

By MedXY 10/05/2025

Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment access and awareness.

Clinical Updates Oncology Specialties Urology

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine

By Dr.Paul 08/07/2025

Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…